Watch CRDF. Know when insiders buy.
One email the day a filing lands. Free.
CRDF
Cardiff Oncology, Inc.
0.86
−0.05 −5.48%
USD · close Oct 26
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
55
WATCH · shorts 55
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $66.9MP/E —DIV YIELD —FCF YIELD —REV TTM $508K −7.0%NET INCOME −$40.1MNET CASH $9.2M52W 0.81 – 3.21SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $104K | −14.0% | — | −$9.6M | −$9.2M | — | -0.14 | −$11.8M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | $41K | −62.4% | — | −$12.8M | −$12.3M | — | -0.18 | −$12.3M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | $243K | +60.9% | — | −$7.8M | −$7.2M | — | -0.11 | −$6M | $0 | −$6M | Feb 24 |
| Q3 2025 · Sep 30 | $120K | −27.3% | — | −$12M | −$11.3M | — | -0.17 | −$10.8M | $18K | −$10.9M | Nov 6 |
| Q2 2025 · Jun 30 | $121K | −25.8% | — | −$14.8M | −$13.9M | — | -0.21 | −$8.3M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | $109K | −46.8% | — | −$14.4M | −$13.4M | — | -0.20 | −$12.8M | — | — | Aug 11 |
| Q4 2024 · Dec 31derived | $151K | −3.2% | — | −$12.6M | −$11.8M | — | -0.21 | −$10.3M | $0 | −$10.3M | Feb 24 |
| Q3 2024 · Sep 30 | $165K | +17.0% | — | −$12.6M | −$11.9M | — | -0.25 | −$10.5M | $0 | −$10.5M | Nov 6 |
| Q2 2024 · Jun 30 | $163K | — | — | −$12.5M | −$11.8M | — | -0.26 | −$9.2M | $0 | −$9.2M | Nov 6 |
| Q1 2024 · Mar 31 | $205K | — | — | −$10.9M | −$10M | — | -0.22 | −$7.7M | $80K | −$7.8M | Nov 6 |
| Q4 2023 · Dec 31derived | $156K | — | — | −$10.3M | −$9.3M | — | -0.21 | −$7.1M | $8K | −$7.1M | Feb 27 |
| Q3 2023 · Sep 30 | $141K | — | — | −$10.8M | −$9.7M | — | -0.22 | −$8M | $315K | −$8.3M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $593K | — | −$49M | −$45.9M | -7732.0% | -0.69 | −$37.9M | $44K | −$38M | — | — |
| FY2024 · to Dec 31 | $683K | — | −$48.7M | −$45.4M | -6651.7% | -0.95 | −$37.7M | $80K | −$37.8M | — | — |
| FY2023 · to Dec 31 | $488K | — | −$45.4M | −$41.4M | -8492.0% | -0.93 | −$30.9M | $582K | −$31.5M | — | — |
| FY2022 · to Dec 31 | $386K | — | −$39.9M | −$38.7M | -10026.9% | -0.89 | −$33.8M | $1M | −$34.8M | — | — |
| FY2021 · to Dec 31 | $359K | — | −$28.9M | −$28.3M | -7880.5% | -0.73 | −$23M | $205K | −$23.2M | — | — |
| FY2020 · to Dec 31 | $366K | — | −$19.1M | −$19.3M | -5275.2% | -1.08 | −$16.3M | $211K | −$16.5M | — | — |
Every number comes from Cardiff Oncology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.